Resignation of DirectorJuliet Hull

NZX/ASX Announcement
28 July 2025

Resignation of Director – Juliet Hull


Truscreen Group Limited (NZX/ASX:TRU) (Truscreen or Company) advises that non-executive
director, Ms Juliet Hull has advised the Company that she will resign as a director with effect from the
date of the forthcoming Annual Shareholder Meeting being 11 September 2025.
Juliet was appointed a Non-Executive Director on 11 September 2020 and stepped up to lead the
Company as Interim Chief Executive Officer, during the Covid years, from February 2021 until
October 2022.
Tony Ho Chairman commented, “on behalf of the Board, I take this opportunity to thank Juliet for a
significant contribution during her tenure, and particularly during the challenging Covid period.
Juliet’s healthcare experience in Asia Pacific has been valuable for Truscreen and her contribution is
much appreciated by fellow board members”.

This announcement has been approved by the Board.


Ends


For more information, visit www.truscreen.com or contact:

Mr Anthony Ho
Chairman
tonyho@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is typically registered as a primary screening device for cervical
cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS
(Mexico). It has Ministry of Health approval for use in Vietnam, Israel and the Philippines, among others
and has distributors in over 20 countries. In 2021, TruScreen established a manufacturing facility in
China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical
Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National
Technical List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the
Russian guidelines for the screening of cervical cancer.
In financial year 2025 alone, approximately 150,000
1
examinations were performed with the
TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico,
Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical cancer”
©
.
To learn more, please visit: www.truscreen.com/.
1
Based on Single Use Sensor sales.